RISK FACTORS, COMORBIDITY AND MORTALITY OF COVID-19 PATIENTSAT ISOLATION CENTER IN AL-KHOMIS CITY, LIBYA
DOI:
https://doi.org/10.59743/jbs.v33i2.177Keywords:
pandemic, COVID 19, epidemiology, clinical characteristic, comorbidity, mortality, LibyaAbstract
Objectives: to estimate the epidemiological characteristics, comorbidity and risk factors among patients with Covid-19 symptoms, who were admitted and hospitalized in the isolation center 1 of Covid 19 in Al-khomis city, Libya.
Methods: A retrospective study on 143 patients whom hospitalized in the isolation center of Covid-19 in Al-Khomis city – Libya from the period of July 10, 2020 to November 26, 2020.
Results: The medical data of 143 patients of Covid-19 were subjected to the statistical analysis. The cases of males were more than females by 10%, and mortality rate among all patients was 26.6%. The study showed that the median age of patients was 63 years, while the average age of death was 70 years. The major complains of Covid-19 patients were fever, fatigue, dyspnea, and cough. The results showed that there was a significant difference between Oxygen saturation or SpO2 levels (average 66.7%) of death group compared with Covid-19 survivors (average 82.28%). The comorbidity among the patients included diabetes 49%, hypertension 30.1%, and respiratory diseases only 2.8%. The statistical analysis of the results revealed no significant difference among all of these diseases and the cause of death among the studied cases.
Conclusion: The males are more than females in the infection rate of Covid-19. Patients aged 63 years or older should be considered as risk, and therefor medical follow up is required. Patients who had SpO2 levels less than 95% should have an urgent medical intervention to control the hypoxia and prevent other severe consequences.
Downloads
References
- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17. PMID: 32081636; PMCID: PMC7127800.
- World Health Organization, WHO Director-General's Opening Remarks at themedia Briefing on COVID-19 - March 11 2020, [cited 2020 December 7]. Available from: URL:https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
- COVID-19 cases top 10,000 in Africa.( 2020).[cited 2020 December 13]. Available from: URL:https://www.afro.who.int/news/covid-19-cases-top-10-000-africa.
-Alhudiri M, Ebrahim O, Sassi A, El Meshri E, Fellah A, Aslougi K, Elzagheid I; Overview of Epidemiology, Pathogenesis and Clinical Aspects of COVID-19: A Libyan Perspective. IOSR 2020 Jul. doi: 10.9790/0853-1907012841. 2279-0861.
-Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24. PMID: 31978945; PMCID: PMC7092803.
- Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243. doi: 10.1073/pnas.2004999117. Epub 2020 Apr 8. PMID: 32269081; PMCID: PMC7196762.
-Motayo BO, Oluwasemowo OO, Olusola BA, Akinduti PA, Arege OT, Obafemi YD, Faneye AO, Isibor PO, Aworunse OS, Oranusi SU. Evolution and genetic diversity of SARS-CoV-2 in Africa using whole genome sequences. Int J Infect Dis. 2021 Feb;103:282-287. doi: 10.1016/j.ijid.2020.11.190. Epub 2020 Nov 28. PMID: 33259879; PMCID: PMC7698667.
-Lovato A, de Filippis C, Marioni G. Upper airway symptoms in coronavirus disease 2019 (COVID-19).Am J Otolaryngol. 2020 May-Jun;41(3):102474. doi: 10.1016/j.amjoto.2020.102474. Epub 2020 Apr 4. PMID: 32278470; PMCID: PMC7128936.
-Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon. 2020 Dec;6(12):e05684. doi: 10.1016/j.heliyon.2020.e05684. Epub 2020 Dec 15. PMID: 33344791; PMCID: PMC7737518.
-Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. PMID: 32091533.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839. PMID: 32648899.
- Kim, J.H., Marks, F. & Clemens, J.D. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 27, 205–211 (2021). https://doi.org/10.1038/s41591-021-01230-y.
- The weekly update of COVID 19 Week 48 / 2020 (23 – 29 Nov.) of the national center for disease control- Libya. [cited 2020 December 16]. Available from: URL:https://drive.google.com/file/d/11OZE3cD2V6EDRhMICTchfyWaKGyVrJz/view.
-Ramón Pérez-Tanoira, Felipe Pérez-García, Juan Romanyk, Gómez-Herruz P, Arroyo T, González R , García L, Expósito C, Moreno J, Gutiérrez I, Mathews A, Ramos E, Garcia L, Troncoso D, Cuadros-González J.Prevalence and risk factors for mortality related to COVID-19 in a severely affected area of Madrid, Spain. medRxiv; 2020 May. doi: https://doi.org/10.1101/2020.05.25.20112912.
- Hu X, Hu C, Yang Y, Chen J, Zhong P, Wen Y, Chen X. Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963035. doi: 10.1177/1753466620963035. PMID: 33138694; PMCID: PMC7649871.
-Chen T, Wu D, Chen H, Yan W, Yang D, Chen G et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study BMJ 2020; 368 :m1091 doi:10.1136/bmj.m1091
-Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683. Erratum in: JAMA. 2020 Apr 28;323(16):1619. PMID: 32203977.
-Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, Siau E. Risk Factors for Mortality in Patients with COVID-19 in New York City. J Gen Intern Med. 2021 Jan;36(1):17-26. doi: 10.1007/s11606-020-05983-z. Epub 2020 Jun 30. PMID: 32607928; PMCID: PMC7325642.
- Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, Li Y, Cheng L, Li W, Jia H, Ma X. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020 Jul 13;12(13):12493-12503. doi: 10.18632/aging.103579. Epub 2020 Jul 13. PMID: 32658868; PMCID: PMC7377860.
-Bajgain, Kalpana Thapa et al. “Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature.” American journal of infection control vol. 49,2 (2021): 238-246. doi:10.1016/j.ajic.2020.06.213
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Journal of Basic Sciences

This work is licensed under a Creative Commons Attribution 4.0 International License.

